Five-year tumor-free survival after aggressive trimodality therapy for T3N0M1b non-small cell lung cancer with synchronous solitary brain metastasis

Gen Thorac Cardiovasc Surg. 2012 Jun;60(6):370-2. doi: 10.1007/s11748-012-0007-5. Epub 2012 May 12.

Abstract

Several recent studies have demonstrated that some patients might benefit from aggressive therapy for thoracic stage I lung cancer and synchronous solitary brain metastasis. However, the indication for the patients with advanced T-stage is still unclear. We herein present a patient with synchronous solitary brain metastasis from non-small cell lung cancer who survived without recurrence for 5 years following surgery after chemotherapy, even though the primary tumor was T3N0 thoracic stage II. Aggressive treatment for both the primary site and brain metastasis may therefore be an effective treatment for locally advanced non-small cell lung cancer patients with synchronous solitary brain metastasis.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Carboplatin / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Humans
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Paclitaxel / administration & dosage
  • Pneumonectomy*
  • Radiosurgery*
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Carboplatin
  • Paclitaxel